Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Orphanet Journal of Rare Diseases Année : 2011

Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients.

Résumé

BACKGROUND: Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder with hypothalamic dysfunction, early morbid obesity with hyperphagia, and specific psychiatric phenotypes including cognitive and behavioural problems, particularly disruptive behaviours and frequent temper outbursts that preclude socialization. A deficit in oxytocin (OT)-producing neurons of the hypothalamic paraventricular nucleus has been reported in these patients. METHODS: In a double-blind, randomised, placebo-controlled study, 24 adult patients with PWS received a single intranasal administration of 24 IU of OT or placebo and were tested 45 min later on social skills. Behaviours were carefully monitored and scored using an in-house grid as follows: over the two days before drug administration, on the half-day following administration, and over the subsequent two days. All patients were in a dedicated PWS centre with more than ten years of experience. Patients are regularly admitted to this controlled environment. RESULTS: Patients with PWS who received a single intranasal administration of OT displayed significantly increased trust in others (P = 0.02) and decreased sadness tendencies (P = 0.02) with less disruptive behaviour (P = 0.03) in the two days following administration than did patients who received placebo. In the half-day following administration, we observed a trend towards less conflict with others (p = 0.07) in the OT group compared with the placebo group. Scores in tests assessing social skills were not significantly different between the two groups. CONCLUSIONS: This study needs to be reproduced and adapted. It nevertheless opens new perspectives for patients with PWS and perhaps other syndromes with behavioural disturbances and obesity. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01038570.

Domaines

Génétique
Fichier principal
Vignette du fichier
1750-1172-6-47.pdf (156.31 Ko) Télécharger le fichier
1750-1172-6-47.xml (57.61 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Loading...

Dates et versions

inserm-00663634 , version 1 (27-01-2012)

Identifiants

Citer

Maïthé Tauber, Carine Mantoulan, Pierre Copet, Joseba Jauregui, Genevieve Demeer, et al.. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients.. Orphanet Journal of Rare Diseases, 2011, 6 (1), pp.47. ⟨10.1186/1750-1172-6-47⟩. ⟨inserm-00663634⟩
216 Consultations
290 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More